Review article: Biofilm formation by Helicobacter pylori as a target for eradication of resistant infection

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 3, 2012, Pages 222-230

  Cammarota, G ^a   Sanguinetti, M ^b   Gallo, A ^a   Posteraro, B ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISMUTH; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; NITROIMIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE; THIAMPHENICOL;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BIOFILM; DRUG TARGETING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION CONTROL; INFECTION RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SCANNING ELECTRON MICROSCOPY; STOMACH BIOPSY; STOMACH EPITHELIUM; STOMACH MUCOSA; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG RESISTANCE, BACTERIAL; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 84863315894     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05165.x     Document Type: Review

References (75)

1. Bavington C, Page C,. Stopping bacterial adhesion: a novel approach to treating infections. Respiration 2005; 72: 335-44. (Pubitemid 41160162)
2. Kandulski A, Selgrad M, Malfertheiner P,. Helicobacter pylori infection: a clinical overview. Dig Liver Dis 2008; 40: 619-26.
3. Marshall BJ, Windsor HM,. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am 2005; 89: 313-44. (Pubitemid 40126820)
4. Herrera V, Parsonnet J,. Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect 2009; 15: 971-6.
5. Macfarlane S, Furrie E, Macfarlane GT, Dillon JF,. Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. Clin Infect Dis 2007; 45: 29-38. (Pubitemid 46984612)
6. van Amsterdam K, van Vliet AH, Kusters JG, van der Ende A,. Of microbe and man: determinants of Helicobacter pylori-related diseases. FEMS Microbiol Rev 2006; 30: 131-56.
7. Andersen LP,. Colonization and infection by Helicobacter pylori in humans. Helicobacter 2007; 12: 12-5. (Pubitemid 350076230)
8. Andersen LP, Rasmussen L,. Helicobacter pylori-coccoid forms and biofilm formation. FEMS Immunol Med Microbiol 2009; 56: 112-5.
9. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG,. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006; 6: 699-709. (Pubitemid 44601991)
10. Cellini L, Grande R, Di Campli E, Di Bartolomeo S, Capodicasa S, Marzio L,. Analysis of genetic variability, antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy. Scand J Gastroenterol 2006; 41: 280-7.
11. Cole SP, Harwood J, Lee R, She R, Guiney DG,. Characterization of monospecies biofilm formation by Helicobacter pylori. J Bacteriol 2004; 186: 3124-32. (Pubitemid 38609756)
12. Cellini L, Grande T, Traini E, et al,. Biofilm formation and modulation of luxS and rpoD expression by Helicobacter pylori. Biofilms 2005; 2: 119-27. (Pubitemid 41425098)
13. Carron MA, Tran VR, Sugawa C, Coticchia JM,. Identification of Helicobacter pylori biofilms in human gastric mucosa. J Gastrointest Surg 2006; 10: 712-7. (Pubitemid 43711142)
14. Coticchia JM, Sugawa C, Tran VR, Gurrola J, Kowalski E, Carron MA,. Presence and density of Helicobacter pylori biofilms in human gastric mucosa in patients with peptic ulcer disease. J Gastrointest Surg 2006; 10: 883-9. (Pubitemid 43870158)
15. Yonezawa H, Osaki T, Kurata S, Zaman C, Hanawa T, Kamiya S,. Assessment of in vitro biofilm formation by Helicobacter pylori. J Gastroenterol Hepatol 2010; 25 (Suppl. 1): S90-4.
16. Cellini L, Grande R, Di Campli E, et al,. Dynamic colonization of Helicobacter pylori in human gastric mucosa. Scand J Gastroenterol 2008; 43: 178-85. (Pubitemid 351161521)
17. Cammarota G, Branca G, Ardito F, et al,. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol 2010; 8: 817-20.
18. Cellini L, Allocati N, Di Campli E, Dainelli B,. Helicobacter pylori: a fickle germ. Microbiol Immunol 1994; 38: 25-30. (Pubitemid 24067684)
19. Lewis K,. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007; 5: 48-56. (Pubitemid 44942303)
20. Lewis K,. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 2008; 322: 107-31.
21. Costerton JW, Stewart PS, Greenberg EP,. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22. (Pubitemid 29289651)
22. Donlan RM, Costerton JW,. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93. (Pubitemid 34303762)
23. Tsuneda S, Aikawa H, Hayashi H, Yuasa A, Hirata A,. Extracellular polymeric substances responsible for bacterial adhesion onto solid surface. FEMS Microbiol Lett 2003; 223: 287-92. (Pubitemid 36776338)
24. Eboigbodin KE, Ojeda JJ, Biggs CA,. Investigating the surface properties of Escherichia coli under glucose controlled conditions and its effect on aggregation. Langmuir 2007; 23: 6691-7. (Pubitemid 46943496)
25. Hall-Stoodley L, Costerton JW, Stoodley P,. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004; 2: 95-108. (Pubitemid 39490064)
26. Hall-Stoodley L, Stoodley P,. Evolving concepts in biofilm infections. Cell Microbiol 2009; 11: 1034-43.
27. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O,. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010; 35: 322-32.
28. Werner E, Roe F, Bugnicourt A, et al,. Stratified growth in Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 2004; 70: 6188-96. (Pubitemid 39471869)
29. Hu FZ, Ehrlich GD,. Population-level virulence factors amongst pathogenic bacteria: relation to infection outcome. Future Microbiol 2008; 3: 31-42. (Pubitemid 351385949)
30. Ehrlich GD, Ahmed A, Earl J, et al,. The distributed genome hypothesis as a rubric for understanding evolution in situ during chronic bacterial biofilm infectious processes. FEMS Immunol Med Microbiol 2010; 59: 269-79.
31. Marshall BJ, Warren JR,. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-5.
32. Stark RM, Gerwig GJ, Pitman RS, et al,. Biofilm formation by Helicobacter pylori. Lett Appl Microbiol 1999; 28: 121-6. (Pubitemid 29078246)
33. Yonezawa H, Osaki T, Kurata S, et al,. Outer membrane vesicles of Helicobacter pylori TK1402 are involved in biofilm formation. BMC Microbiol 2009; 9: 197.
34. Schooling SR, Beveridge TJ,. Membrane vesicles: an overlooked component of the matrices of biofilms. J Bacteriol 2006; 188: 5945-57. (Pubitemid 44384103)
35. Yonezawa H, Osaki T, Woo T, et al,. Analysis of outer membrane vesicle protein involved in biofilm formation of Helicobacter pylori. Anaerobe 2011; 17: 388-90.
36. Jayaraman A, Wood TK,. Bacterial quorum sensing: signals, circuits, and implications for biofilms and disease. Annu Rev Biomed Eng 2008; 10: 145-67.
37. Hardie KR, Heurlier K,. Establishing bacterial communities by 'word of mouth': LuxS and autoinducer 2 in biofilm development. Nat Rev Microbiol 2008; 6: 635-43. (Pubitemid 352006105)
38. Merritt J, Qi F, Goodman SD, Anderson MH, Shi W,. Mutation of luxS affects biofilm formation in Streptococcus mutans. Infect Immun 2003; 71: 1972-9. (Pubitemid 36368730)
39. Prakobphol A, Tangemann K, Rosen SD, Hoover CI, Leffler H, Fisher SJ,. Separate oligosaccharide determinants mediate interactions of the low-molecular-weight salivary mucin with neutrophils and bacteria. Biochemistry 1999; 38: 6817-25.
40. Cole SP, Cirillo D, Kagnoff MF, Guiney DG, Eckmann L,. Coccoid and spiral Helicobacter pylori differ in their abilities to adhere to gastric epithelial cells and induce interleukin-8 secretion. Infect Immun 1997; 65: 843-6. (Pubitemid 27053985)
41. Kusters JG, van Vliet AH, Kuipers EJ,. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19: 449-90. (Pubitemid 44134306)
42. Ishijima N, Suzuki M, Ashida H, et al,. BabA-mediated adherence is a potentiator of the Helicobacter pylori type IV secretion system activity. J Biol Chem 2011; 286: 25256-64.
43. Kawakubo M, Ito Y, Okimura Y, et al,. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004; 305: 1003-6. (Pubitemid 39071775)
44. Kobayashi M, Lee H, Nakayama J, Fukuda M,. Roles of gastric mucin-type O-glycans in the pathogenesis of Helicobacter pylori infection. Glycobiology 2009; 19: 453-61.
45. Shu M, Browngardt CM, Chen YY, Burne RA,. Role of urease enzymes in stability of a 10-species oral biofilm consortium cultivated in a constant-depth film fermenter. Infect Immun 2003; 71: 7188-92. (Pubitemid 37475355)
46. Hall-Stoodley L, Nistico L, Sambanthamoorthy K, et al,. Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in Streptococcus pneumoniae clinical isolates. BMC Microbiol 2008; 8: 173.
47. Grande R, Di Giulio M, Bessa LJ, et al,. Extracellular DNA in Helicobacter pylori biofilm: a backstairs rumour. J Appl Microbiol 2011; 110: 490-8.
48. Baltrus DA, Guillemin K, Phillips PC,. Natural transformation increases the rate of adaptation in the human pathogen Helicobacter pylori. Evolution 2008; 62: 39-49.
49. Fuccio L, Zagari RM, Minardi ME, Bazzoli F,. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 25: 133-41. (Pubitemid 46046370)
50. Lee YC, Liou JM, Wu MS, Wu CY, Lin JT,. Eradication of Helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone. Therap Adv Gastroenterol 2008; 1: 111-20.
51. Malfertheiner P, Megraud F, O'Morain C, et al,. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81. (Pubitemid 46854190)
52. Chey WD, Wong BCY,. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25. (Pubitemid 47206706)
53. Gisbert JP, Calvet X,. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011; 34: 604-17.
54. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, et al,. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010; 31: 1077-84.
55. O'Connor A, Gisbert JP, McNamara D, O'Morain C,. Treatment of Helicobacter pylori infection 2011. Helicobacter 2011; 16 (Suppl. 1): S53-8.
56. Gisbert JP, Calvet X,. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34: 1255-68.
57. Katelaris PH,. Helicobacter pylori: antibiotic resistance and treatment options. J Gastroenterol Hepatol 2009; 24: 1155-7.
58. Miura S, Hokari R,. Seeking an optimal eradication therapy for Helicobacter pylori infection. J Gastroenterol Hepatol 2012; 27: 7-9.
59. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD,. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73.
60. Katelaris PH, Forbes GM, Talley NJ, Crotty B,. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002; 123: 1763-9. (Pubitemid 35408299)
61. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J,. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-7. (Pubitemid 36348526)
62. Gisbert JP,. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14: 5385-402.
63. Boles BR, Singh PK,. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. Proc Natl Acad Sci USA 2008; 105: 12503-8.
64. Ramsey MM, Whiteley M,. Polymicrobial interactions stimulate resistance to host innate immunity through metabolite perception. Proc Natl Acad Sci USA 2009; 106: 1578-83.
65. Aslam S,. Effect of antibacterials on biofilms. Am J Infect Control 2008; 36: S175.
66. Donlan RM,. Biofilms on central venous catheters: is eradication possible? Curr Top Microbiol Immunol 2008; 322: 133-61.
67. El-Azizi M, Rao S, Kanchanapoom T, Khardori N,. In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci. Ann Clin Microbiol Antimicrob 2005; 4: 2.
68. Aslam S, Trautner BW, Ramanathan V, Darouiche RO,. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother 2007; 51: 1556-8. (Pubitemid 46586852)
69. Fraternale A, Paoletti MF, Casabianca A, et al,. GSH and analogs in antiviral therapy. Mol Aspects Med 2009; 30: 99-110.
70. Zuin R, Palamidese A, Negrin R, Catozzo L, Scarda A, Balbinot M,. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2005; 25: 401-8. (Pubitemid 41019987)
71. Macchi A, Ardito F, Marchese A, Schito GC, Fadda G,. Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms. J Chemother 2006; 18: 507-13.
72. Aslam S, Darouiche RO,. Role of antibiofilm-antimicrobial agents in controlling device-related infections. Int J Artif Organs 2011; 34: 752-8.
73. Huynh HQ, Couper RT, Tran CD, Moore L, Kelso R, Butler RN,. N-acetylcysteine, a novel treatment for Helicobacter pylori infection. Dig Dis Sci 2004; 49: 1853-61. (Pubitemid 40228551)
74. Gurbuz AK, Ozel AM, Ozturk R, Yildirim S, Yazgan Y, Demirturk L,. Effect of N-acetyl cysteine on Helicobacter pylori. South Med J 2005; 98: 1095-7. (Pubitemid 41780349)
75. Fraternale A, Paoletti MF, Casabianca A, et al,. Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. Curr Med Chem 2006; 13: 1749-55. (Pubitemid 43871753)